Advances in PET myocardial perfusion imaging: F-18 labeled tracers

Annals of Nuclear Medicine

Volumn 26, Issue 1, 2012, Pages 1-6

  Rischpler, Christoph ^a   Park, Min Jae ^b   Fung, George S K ^b   Javadi, Mehrbod ^b   Tsui, Benjamin M W ^b   Higuchi, Takahiro ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

FBnTP; Flurpiridaz; Ischemic heart disease; Myocardial perfusion; PET

Indexed keywords

FLUORINE 18; FLUOROBENZYLTRIPHENYLPHOSPHONIUM F 18; FLURPIRIDAZ F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROGEN 13; OXYGEN 15; RUBIDIUM 82; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201; UNCLASSIFIED DRUG;

CORONARY ARTERY DISEASE; DRUG HALF LIFE; DRUG STRUCTURE; MYOCARDIAL PERFUSION IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BIOLOGICAL TRANSPORT; CLINICAL TRIALS AS TOPIC; FLUORINE RADIOISOTOPES; HUMANS; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 84858706033     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0552-5     Document Type: Review

References (37)

1. Beller GA, Bergmann SR. Myocardial perfusion imaging agents: SPECT and PET. J Nucl Cardiol. 2004;11:71-86. (Pubitemid 38219572)
2. Russell RR, Zaret BL. Nuclear cardiology: present and future. Curr Probl Cardiol. 2006;31:557-629. (Pubitemid 44279870)
3. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation. 2003;108:1404-18. (Pubitemid 37174421)
4. Higuchi T, Bengel FM. Cardiovascular nuclear imaging: from perfusion to molecular function: non-invasive imaging. Heart. 2008;94:809-16. (Pubitemid 351744708)
5. Bateman TM. Cardiac positron emission tomography and the role of adenosine pharmacologic stress. Am J Cardiol. 2004;94:19-24.
6. Cecchin D, Zucchetta P, Faggin P, Bolla E, Bui F. 99Mo/99mTc generator shortage: free, Web-based software. J Nucl Med. 2010;51:14-5.
7. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol. 2006;13:24-33. (Pubitemid 43192726)
8. Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol. 2009;54:1-15.
9. Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008;15:745-53.
10. Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, et al. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2010;51:1592-9.
11. Lautamaki R, George RT, Kitagawa K, Higuchi T, Merrill J, Voicu C, et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol Imaging. 2009;36:576-86.
12. Heller GV, Calnon D, Dorbala S. Recent advances in cardiac PET and PET/CT myocardial perfusion imaging. J Nucl Cardiol. 2009;16:962-9.
13. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 1996;37:1701-12. (Pubitemid 26337184)
14. Park SJ, Rogers WL, Clinthorne NH. Effects of positron range and annihilation photon acolinearity on image resolution of a Compton PET. IEEE Trans Nucl Sci. 2007;54:1543-52. (Pubitemid 47599124)
15. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim Biophys Acta. 1998;1364:222-35. (Pubitemid 28291841)
16. Yalamanchili P, Wexler E, Hayes M, Yu M, Bozek J, Kagan M, et al. Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent. J Nucl Cardiol. 2007;14:782-8. (Pubitemid 350082573)
17. Ravert HT, Madar I, Dannals RF. Radiosynthesis of 3-[F-18]fluoropropyl and 4-[F-18]fluorobenzyl triarylphosphonium ions. J Label Comp Radiopharm. 2004;47:469-76. (Pubitemid 39062538)
18. Madar I, Isoda T, Finley P, Angle J, Wahl R. 18F-fluorobenzyl triphenyl phosphonium: a noninvasive sensor of brown adipose tissue thermogenesis. J Nucl Med. 2011;52:808-14.
19. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol. 2007;14:789-98. (Pubitemid 350082572)
20. Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008;49:630-6. (Pubitemid 351520612)
21. Muzik O, Beanlands RS, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med. 1993;34:83-91. (Pubitemid 23014231)
22. Leppo JA, Meerdink DJ. Comparison of the myocardial uptake of a technetium-labeled isonitrile analogue and thallium. Circ Res. 1989;65:632-9. (Pubitemid 19226439)
23. Mullani NA, Goldstein RA, Gould KL, Marani SK, Fisher DJ, O'Brien HA, et al. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors. J Nucl Med. 1983;24:898-906. (Pubitemid 14236772)
24. Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, et al. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med. 2006;47:1359-66. (Pubitemid 47544892)
25. Madar I, Liu T, O'Rourke B. Novel technique for dynamic PET imaging in isolated perfused hearts. J Nucl Med. 2011;52:333.
26. Madar I, Ravert H, Dipaula A, Du Y, Dannals RF, Becker L. Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med. 2007;48:1021-30. (Pubitemid 46909933)
27. Higuchi T, Nekolla SG, Huisman MM, Reder S, Poethko T, Yu M, et al. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med. 2008;49:1715-22.
28. Sherif HM, Saraste A, Weidl E, Weber AW, Higuchi T, Reder S, et al. Evaluation of a novel (18)F-labeled positron-emission tomography perfusion tracer for the assessment of myocardial infarct size in rats. Circ Cardiovasc Imaging. 2009;2:77-84.
29. Yu M, Bozek J, Guaraldi M, Kagan M, Azure M, Robinson SP. Cardiac imaging and safety evaluation of BMS747158, a novel PET myocardial perfusion imaging agent, in chronic myocardial compromised rabbits. J Nucl Cardiol. 2010;17:631-6.
30. Sherif HM, Nekolla SG, Saraste A, Reder S, Yu M, Robinson S, et al. Simplified quantification of myocardial flow reserve with flurpiridaz F 18: validation with microspheres in a pig model. J Nucl Med. 2011;52:617-24.
31. Nekolla SG, Saraste A. Novel F-18-labeled PET myocardial perfusion tracers: bench to bedside. Curr Cardiol Rep. 2011;13:145-50.
32. Higuchi T, Fukushima K, Rischpler C, Isoda T, Javadi MS, Ravert H, et al. Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion. J Nucl Med. 2011;52:965-9.
33. Maddahi J, Berman D, Taillefer R, Udelson J, Devine M, Lazewatsky J, et al. Phase 2 clinical comparison of flurpiridaz F 18 injection PET, SPECT myocardial perfusion imaging for diagnosis of coronary artery disease. J Nucl Med. 2011;52:59.
34. Maddahi J, Czernin J, Berman D, Taillefer R, Devine M, Lazewatsky J, et al. Comparison of flurpiridaz F 18 PET injection, Tc-99m labeled SPECT myocardial perfusion imaging for identifying severity, extent of stress induced myocardial ischemia in phase 2 clinical trials. J Nucl Med. 2011;52:444.
35. Rozanski A, Gransar H, Hayes SW, Friedman JD, Hachamovitch R, Berman DS. Comparison of long-term mortality risk following normal exercise vs adenosine myocardial perfusion SPECT. J Nucl Cardiol. 2010;17:999-1008.
36. Chow BJW, Beanlands RS, Lee A, DaSilva JN, deKemp RA, Alkahtani A, et al. Treadmill exercise produces larger perfusion defects than dipyridamole stress N-13 ammonia positron emission tomography. J Am Coll Cardiol. 2006;47:411-6. (Pubitemid 43063264)
37. Levine MG, Ahlberg AW, Mann A, White MP, McGill CC, de Leon CM, et al. Comparison of exercise, dipyridamole, adenosine, and dobutamine stress with the use of Tc-99m tetrofosmin tomographic imaging. J Nucl Cardiol. 1999;6:389-96. (Pubitemid 29405960)